Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176951 | 0.76 | CHRNB2 (0.47) | POLBSMN1; SMN2 | |
| SCHEMBL6176949 | 0.76 | CHRNB2 (0.47) | POLBSMN1; SMN2 | |
| SCHEMBL7012875 | 0.74 | MEN1 (0.49) | POLBSMN1; SMN2 | |
| SCHEMBL3871908 | 0.74 | CYP19A1 (0.33) | ALDH1A1POLBSMN1; SMN2HCAR2PKM | |
| SCHEMBL25326994 | 0.73 | ALDH1A1 (0.33) | ALDH1A1POLBSMN1; SMN2PKM | |
| SCHEMBL9362322 | 0.73 | MEN1 (0.47) | POLBSMN1; SMN2 | |
| SCHEMBL451612 | 0.72 | SLC18A3 (0.43) | — | |
| SCHEMBL1639225 | 0.72 | SLC18A3 (0.43) | — | |
| SCHEMBL1638075 | 0.72 | SLC18A3 (0.43) | — | |
| SCHEMBL7669379 | 0.72 | HTR3A (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | claimed |
| US-5210193-A | Bactericide | AMERICAN CYANAMID COMPANY (US) | 1993-05-11 | — | — | US | claimed |
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | UNIV OREGON HEALTH & SCIENCE (US) | 2023-06-08 | — | — | US | disclosed |
| CN-115996908-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2023-04-21 | — | — | CN | disclosed |
| EP-4143163-A1 | ANTAGONISTS OF GPR39 PROTEIN | Oregon Health & Science University (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222858-A1 | ANTAGONISTS OF GPR39 PROTEIN | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-11-04 | — | — | WO | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
| US-5210193-A | Bactericide | AMERICAN CYANAMID COMPANY (US) | 1993-05-11 | — | — | US | disclosed |
| US-4940710-A | 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | PARP1 2267/4885ALDH1A1 3510/4885POLB 4649/4885 |
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | GPR39, GPR139, GPR119 | PARP1 4728/4885ALDH1A1 3167/4885POLB 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.